NASDAQ · LLY
Healthcare · Drug Manufacturers - General
$1,170.14
Down-$17.44 (-1.49%)
Updated Sep 23, 2026, 11:13 PM
SID Score
6.1/10
Composite research score
Smart Money
46/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
LLY closed at $1,170.14 after 20 trading sessions, down 5.15% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 22, 2026 | $1,146.15 | $1,180.53 | $1,139.26 | $1,170.14 | 2.45M |
| Sep 21, 2026 | $1,144.495 | $1,170.8999 | $1,134.41 | $1,164.89 | 2.48M |
| Sep 18, 2026 | $1,150.00 | $1,157.60 | $1,140.27 | $1,152.93 | 4.55M |
| Sep 17, 2026 | $1,150.27 | $1,159.75 | $1,138.26 | $1,152.44 | 1.9M |
| Sep 16, 2026 | $1,137.31 | $1,151.23 | $1,132.63 | $1,137.82 | 1.48M |
| Sep 15, 2026 | $1,156.63 | $1,161.00 | $1,131.59 | $1,136.11 | 1.89M |
| Sep 14, 2026 | $1,142.20 | $1,153.95 | $1,130.5001 | $1,138.28 | 2.13M |
| Sep 11, 2026 | $1,129.405 | $1,131.44 | $1,113.2919 | $1,115.70 | 1.84M |
| Sep 10, 2026 | $1,126.08 | $1,133.79 | $1,120.52 | $1,123.00 | 2M |
| Sep 9, 2026 | $1,127.61 | $1,138.79 | $1,119.00 | $1,124.21 | 2.05M |
| Sep 8, 2026 | $1,133.00 | $1,134.53 | $1,113.55 | $1,123.91 | 2.4M |
| Sep 4, 2026 | $1,150.61 | $1,158.44 | $1,138.306 | $1,149.36 | 2.22M |
| Sep 3, 2026 | $1,170.00 | $1,171.66 | $1,137.50 | $1,159.60 | 2.55M |
| Sep 2, 2026 | $1,164.15 | $1,187.83 | $1,158.00 | $1,160.08 | 2.45M |
| Sep 1, 2026 | $1,188.00 | $1,188.325 | $1,156.8501 | $1,160.00 | 2.52M |
| Aug 31, 2026 | $1,168.47 | $1,171.4479 | $1,147.00 | $1,156.73 | 3.06M |
| Aug 28, 2026 | $1,172.66 | $1,180.00 | $1,162.93 | $1,174.61 | 2.45M |
| Aug 27, 2026 | $1,182.25 | $1,190.11 | $1,171.71 | $1,176.10 | 2.74M |
| Aug 26, 2026 | $1,234.00 | $1,235.775 | $1,180.01 | $1,189.41 | 3.01M |
| Aug 25, 2026 | $1,249.00 | $1,264.73 | $1,229.79 | $1,233.66 | 2.14M |
The latest Smart Investors Daily articles mentioning LLY.
LLY research
Company profile and research snapshot.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 22, 2026 | TD Cowen | Buy | — |
| Sep 18, 2026 | Guggenheim | Buy | — |
| Sep 10, 2026 | HSBC | Reduce | — |
| Aug 7, 2026 | Truist Securities | Buy | — |
| Aug 6, 2026 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 23, 2026
AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.
Yahoo · Sep 23, 2026
Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.
Yahoo · Sep 23, 2026
Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.
Yahoo · Sep 23, 2026
NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1.
Interpretive context generated from the platform’s current data sources.
Eli Lilly and Company shares closed at $1,170.48, reflecting a daily decline of 1.66% per SID market data. Over the trailing one-month period, LLY has fallen 6.39%, though the stock has gained 5.70% over three months and 9.67% over the past year. The stock currently trades slightly below its 50-day moving average of $1,176.89 but remains well above its 200-day moving average of $1,061.98, indicating a longer-term uptrend despite near-term softness. The 14-day relative strength index sits at 54.0, placing LLY in neutral territory with no overbought or oversold signals. Average daily trading volume stands at approximately 3.80 million shares, according to Massive/Polygon data. Eli Lilly maintains a market capitalization of approximately $906.5 billion and exhibits a beta of 0.369, reflecting substantially lower volatility relative to the broader market, consistent with the defensive characteristics typical of large-cap healthcare equities.
Eli Lilly trades at a price-to-earnings ratio of 49.16, a significant premium relative to the broader healthcare sector, reflecting the market's pricing of robust future growth expectations, per SID market data. The company's PEG ratio stands at 1.47, suggesting the earnings growth rate partially justifies the elevated P/E multiple but does not indicate deep undervaluation. Eli Lilly's price-to-book ratio of 38.04 further underscores the premium valuation, driven largely by intangible assets tied to the company's pharmaceutical pipeline, according to SEC filings. The dividend yield currently sits at approximately 0.59%, a modest level that positions LLY primarily as a growth-oriented holding rather than an income vehicle. Within the healthcare sector, Eli Lilly's valuation metrics rank among the highest, a reflection of the company's dominant position in GLP-1 receptor agonist therapies and strong revenue trajectory. Investors are paying a substantial premium for anticipated earnings acceleration in coming quarters.
Eli Lilly's composite smart money score stands at 46 out of 100 with a neutral signal, per SID market data. The institutional sub-score registers a perfect 25 out of 25, indicating maximum confidence from large fund managers and sustained accumulation by major institutional holders. In contrast, the insider activity sub-score is notably lower at 4.1 out of 25. According to SEC Form 4 filings, there have been 9 insider transactions in the last 90 days, comprising 5 purchases and 4 sales, reflecting a roughly balanced pattern among company executives and directors. The dark pool activity sub-score is 9.2 out of 25, suggesting moderate but not outsized off-exchange trading interest. Congressional trading activity scores 7.6 out of 25, per 13F institutional filings and congressional disclosure records. The divergence between the strong institutional conviction and the relatively muted insider score is noteworthy, as institutional holders appear more aggressively positioned than company insiders during this period. Overall, smart money signals present a mixed but institutionally supported profile for LLY.
Eli Lilly has delivered consecutive earnings beats across its three most recent reported quarters, according to company earnings reports. In the most recently reported quarter, the company posted earnings per share of $8.55 versus analyst estimates of $6.85, representing a $1.70 positive surprise. The prior quarter saw EPS of $8.38 against expectations of $6.01, an upside surprise of $2.37, which marked the largest beat in the trailing three-quarter window. The quarter before that produced EPS of $7.54 versus the $6.96 consensus, a $0.58 beat. Looking ahead, analyst estimates project EPS of $8.84 for the upcoming quarter with results expected on August 6, 2026. The pattern of substantial outperformance, averaging approximately $1.55 above consensus across the last three quarters, suggests analysts may still be underestimating Eli Lilly's earnings power, particularly as GLP-1 therapy revenues continue to scale. Revenue growth dynamics remain central to consensus revisions.
Wall Street consensus on Eli Lilly remains predominantly bullish, per SID consensus data. In the most recent rating actions, Guggenheim reiterated a Buy rating on September 18, 2026, while Truist Securities also maintained its Buy recommendation on August 7, 2026, following the company's earnings release. Wells Fargo and Cantor Fitzgerald both reiterated Overweight ratings on August 6, 2026, reinforcing the positive institutional outlook, according to Wall Street analyst reports. The sole dissenting voice among recent coverage comes from HSBC, which maintained its Reduce rating on September 10, 2026. Of the five most recent analyst actions tracked, four reflect bullish or overweight positioning, representing an 80% positive skew among active coverage updates. Notably, all five ratings were reiterations rather than upgrades or downgrades, indicating stable conviction levels on both sides. The prevailing bullish consensus aligns with Eli Lilly's strong earnings trajectory and dominant competitive positioning within the GLP-1 therapeutics market that continues to drive institutional interest.
The latest Smart Investors Daily articles mentioning LLY.
